Cervical cancer screening

-Automatic translation

HIV infected

• Can follow the same age criteria for screening as HIV-negative individuals

• In case of abnormal samples during screening, the follow-up should be the same as for HIV-negative individuals

• Individuals who have needed treatment for a precancerous lesion need annual monitoring throughout their lives

Organ recipients and stem cell recipients

• Need special evaluation from a gynecologist on treatment and possibly a new screening sample

• Important to inform about increased risk for abnormal cell growth

• Screening after treatment should be every 3 years

• In case of abnormal samples during screening, the follow-up is the same as for healthy individuals

• Follow-up throughout their lives

Immunosuppressed women (e.g. due to immunosuppressive drugs for rheumatic disease, inflammatory disease)

• There is no reason for increased monitoring

• Able to follow standard screening guidelines